Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07366112 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

Name: CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment — clinical trial record (NCT07366112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DNACDKHR

StatusRecruiting

PhasePhase 2

SponsorPeking University People's Hospital

Started2026-04-20

View on ClinicalTrials.gov ↗

Amendment history

2026-07-10

Study Status, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-02-01→confirmed 2026-04-20

Study sites0→1

2026-01-18

Original filing

Peking University People's Hospital

220 trials monitored

See 6 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy

Trial Details

NCT Number	NCT07366112
Lead Sponsor	Peking University People's Hospital
Conditions	Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer, ctDNA Monitoring
Enrollment	158 participants
Start Date	2026-04-20
Primary Completion	2028-01-01 (estimated)
Study Completion	2029-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-13